Bayesian population finding with biomarkers in a randomized clinical trial

The identification of good predictive biomarkers allows investigators to optimize the target population for a new treatment. We propose a novel utility-based Bayesian population finding (BaPoFi) method to analyze data from a randomized clinical trial with the aim of finding a sensitive patient population. Our approach is based on casting the population finding process as a formal decision problem together with a flexible probability model, Bayesian additive regression trees (BART), to summarize observed data. The proposed method evaluates enhanced treatment effects in patient subpopulations based on counter-factual modeling of responses to new treatment and control for each patient. In extensive simulation studies, we examine the operating characteristics of the proposed method. We compare with a Bayesian regression-based method that implements shrinkage estimates of subgroup-specific treatment effects. For illustration, we apply the proposed method to data from a randomized clinical trial.

[1]  H. Chipman,et al.  Bayesian CART Model Search , 1998 .

[2]  J. M. Taylor,et al.  Subgroup identification from randomized clinical trial data , 2011, Statistics in medicine.

[3]  A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II) , 2012, BMC Cancer.

[4]  J. Friedman Multivariate adaptive regression splines , 1990 .

[5]  R. Simon,et al.  Bayesian subset analysis. , 1991, Biometrics.

[6]  Michael Branson,et al.  Bayesian models for subgroup analysis in clinical trials , 2011, Clinical trials.

[7]  Michael L Maitland,et al.  Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. , 2007, Journal of the National Cancer Institute.

[8]  D. Sargent,et al.  Clinical trial designs incorporating predictive biomarkers. , 2016, Cancer treatment reviews.

[9]  J Jack Lee,et al.  Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Abdus S Wahed,et al.  Bayesian Nonparametric Estimation for Dynamic Treatment Regimes With Sequential Transition Times , 2014, Journal of the American Statistical Association.

[11]  H. Chipman,et al.  BART: Bayesian Additive Regression Trees , 2008, 0806.3286.

[12]  Donald B. Rubin,et al.  Bayesian Inference for Causal Effects: The Role of Randomization , 1978 .

[13]  R. Simon,et al.  Bayesian subset analysis: application to studying treatment‐by‐gender interactions , 2002, Statistics in medicine.

[14]  Lisa M. McShane,et al.  Effective Incorporation of Biomarkers into Phase II Trials , 2009, Clinical Cancer Research.

[15]  Jennifer L. Hill,et al.  Bayesian Nonparametric Modeling for Causal Inference , 2011 .

[16]  Purushottam W. Laud,et al.  A Bayesian subgroup analysis with a zero‐enriched Polya Urn scheme , 2011, Statistics in medicine.

[17]  Lei Chen,et al.  The mean does not mean as much anymore: finding sub-groups for tailored therapeutics , 2010, Clinical trials.

[18]  I. Lipkovich,et al.  Subgroup identification based on differential effect search—A recursive partitioning method for establishing response to treatment in patient subpopulations , 2011, Statistics in medicine.

[19]  Susan Groshen,et al.  The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee , 2010, Clinical Cancer Research.

[20]  Adrian F. M. Smith,et al.  A Bayesian CART algorithm , 1998 .

[21]  N. Ikeda,et al.  Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.